Champions Oncology (CSBR) Stock: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$4.94
0.06 (1.23%)
â˛
5d:
+0.82%
30d:
-4.08%
90d:
-15.56%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Sep 21, 2026
0d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CSBR is fairly priced but lacks strong directional signals. At -4.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CSBR is fairly priced but lacks strong directional signals. At -4.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $4.94, which is considered slightly low relative to its 30-day fair value range of $4.89 to $5.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 49.4) compared to its historical average (56.1). Remarkably, the market is currently pricing in an annual earnings decline of 4.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CSBR is in a strong downtrend. Immediate support is located at $4.79, while resistance sits at $5.31.
Market Sentiment: CSBR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+142.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CSBR is in a strong downtrend. Immediate support is located at $4.79, while resistance sits at $5.31.
Market Sentiment: CSBR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+142.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.89 -
$5.17
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 142.9% below Wall St target ($12.00)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.89 -
$5.17
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.79
Resistance Level
$5.31
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
49.40
Wall Street Target
$12.00
(+142.9%)
Revenue Growth (YoY)
8.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-1.9%
Valuation Discount vs History
-4.1% cheaper
PE vs Historical
49.4 vs 56.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.1%
(market-implied from PE analysis)
1-Year Target
$4.74
(-4%)
2-Year Target
$4.54
(-8%)
3-Year Target
$4.36
(-12%)
3-Yr Target (if PE normalizes)
(PE: 49â56)
$4.95
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 49.4, Growth: -16.7%)
$3.60
(+-27%)
Base:
(SPY PE: 20.4, Growth: -16.7%)
$1.49
(-70%)
Bear:
(PE: 17.3, Growth: -16.7%)
$1.26
(-74%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 49.4 to 56.1
Stabilization Target:
$5.61
(+13.6%)
PE Expansion Potential:
+13.6%
Share & Embed Analysis
Last updated: October 03, 2026 1:16 PM ET
Data refreshes hourly during market hours. Next update: 2:16 PM
Data refreshes hourly during market hours. Next update: 2:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
